Equity Profile

TMO

Thermo Fisher Scientific Inc.

Health CareLife Sciences Tools & Services$220.3B

Jul22Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Thermo Fisher Scientific Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability, indicating how much money the company makes for each share of stock.

Expected to be around $5.44.

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TMO Q2-2026 Earnings Preview

Context

Company Snapshot

Thermo Fisher Scientific Inc. is a leading company in the health care sector, specializing in life sciences tools and services. Their products are essential for research and development in various fields, including pharmaceuticals and diagnostics, making them a key player in advancing health care solutions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.04%

Avg Stock Reaction

+0.93%

Last Quarter Recap

In Q1-2026, Thermo Fisher reported an EPS of $5.44, surpassing expectations by 4.68%. However, the stock declined by 9.20% the following day, indicating market concerns despite the positive earnings surprise.

Management Promises & Guidance

Management emphasized their commitment to innovation in life sciences tools.
They highlighted ongoing investments in research and development.
Management expressed confidence in maintaining strong customer relationships.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Thermo Fisher's upcoming earnings, given their strong track record of beating EPS estimates. However, the lack of revenue guidance and recent stock performance raises some concerns.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal robust demand for its products, leading to a positive market reaction.

Bear Case

On the other hand, if the earnings report reveals any weakness in revenue growth or margins, it could lead to a significant sell-off, especially given the recent stock decline.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $5.44.

EPS is a critical measure of profitability, indicating how much money the company makes for each share of stock.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is crucial for long-term success.

Gross Margin

Not available.

Gross margin indicates the efficiency of production and pricing strategy, affecting overall profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, the actual EPS figure will be crucial for market sentiment.

What insights can management provide on revenue growth?

Investors are keen to understand the company's growth trajectory, especially in light of recent stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Thermo Fisher to exceed EPS expectations again, given their strong track record.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating strong operational execution.

Despite recent stock performance, there are no signs of significant demand weakness in their key markets.

Key Risk

If the EPS comes in below $5.20, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued earnings growth against concerns about revenue stability.

Bull Confirmed If

An EPS of $5.50 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $5.20 could indicate underlying issues and lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±14.5%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.5% while TMO has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.3%

Calls (221K)P/C Ratio: 0.37Puts (485K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Thermo Fisher beats expectations and raises guidance, history suggests the stock could react positively, averaging a +0.93% move.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess.

Miss

If the company misses EPS expectations, history suggests a potential decline, with an average reaction of -9.20% following previous misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in life sciences tools.
2Insights into customer demand trends in key segments.
3Management's outlook on R&D investments and their impact on future growth.
4Comments on competitive pressures in the life sciences industry.
5Any guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

Thermo Fisher Scientific Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of profitability, indicating how much money the company makes for each share of stock.

Expected to be around $5.44.

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is crucial for long-term success.

Not available.

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TMO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.04%

Avg Stock Reaction

+0.93%

Last Quarter Recap

Management Promises & Guidance

Management emphasized their commitment to innovation in life sciences tools.
They highlighted ongoing investments in research and development.
Management expressed confidence in maintaining strong customer relationships.

Expectations

Wall Street Expectations

Bull Case

If the company continues its trend of beating EPS estimates, it could signal robust demand for its products, leading to a positive market reaction.

Bear Case

On the other hand, if the earnings report reveals any weakness in revenue growth or margins, it could lead to a significant sell-off, especially given the recent stock decline.

Key Metrics to Watch

Earnings Per Share (EPS)

Expected to be around $5.44.

EPS is a critical measure of profitability, indicating how much money the company makes for each share of stock.

Revenue Growth

Not available.

Revenue growth reflects the company's ability to increase sales and expand its market presence, which is crucial for long-term success.

Gross Margin

Not available.

Gross margin indicates the efficiency of production and pricing strategy, affecting overall profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, the actual EPS figure will be crucial for market sentiment.

What insights can management provide on revenue growth?

Investors are keen to understand the company's growth trajectory, especially in light of recent stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Thermo Fisher to exceed EPS expectations again, given their strong track record.

Supporting Evidence

The company has consistently beaten EPS estimates in the past, indicating strong operational execution.

Despite recent stock performance, there are no signs of significant demand weakness in their key markets.

Key Risk

If the EPS comes in below $5.20, it could challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued earnings growth against concerns about revenue stability.

Bull Confirmed If

An EPS of $5.50 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $5.20 could indicate underlying issues and lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±14.5%

Historical Avg

±4.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±14.5% while TMO has averaged ±4.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

41.3%

Calls (221K)P/C Ratio: 0.37Puts (485K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Thermo Fisher beats expectations and raises guidance, history suggests the stock could react positively, averaging a +0.93% move.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess.

Miss

If the company misses EPS expectations, history suggests a potential decline, with an average reaction of -9.20% following previous misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in life sciences tools.
2Insights into customer demand trends in key segments.
3Management's outlook on R&D investments and their impact on future growth.
4Comments on competitive pressures in the life sciences industry.
5Any guidance on revenue expectations for the next quarter.